Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Bardelli A, Siena S.

J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25. Review.

PMID:
20100961
2.

Src kinases as therapeutic targets for cancer.

Kim LC, Song L, Haura EB.

Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. doi: 10.1038/nrclinonc.2009.129. Review.

PMID:
19787002
3.

Nuclear EGFR contributes to acquired resistance to cetuximab.

Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL.

Oncogene. 2009 Oct 29;28(43):3801-13. doi: 10.1038/onc.2009.234. Epub 2009 Aug 17.

4.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F.

Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. doi: 10.1038/nrclinonc.2009.111. Epub 2009 Jul 28. Review.

PMID:
19636327
5.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Engelman JA.

Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664. Review.

PMID:
19629070
6.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F.

Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.

7.

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM.

Cancer Biol Ther. 2009 Apr;8(8):696-703. Epub 2009 Apr 22.

8.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
9.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

10.

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR.

Clin Cancer Res. 2008 Jul 1;14(13):4284-91. doi: 10.1158/1078-0432.CCR-07-5226.

11.

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.

Hantschel O, Rix U, Superti-Furga G.

Leuk Lymphoma. 2008 Apr;49(4):615-9. doi: 10.1080/10428190801896103. Review.

PMID:
18398720
12.

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM.

Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659. Erratum in: Cancer Res. 2009 Dec 1;69(23):9156. Cancer Res. 2008 Aug 15;68(16):6859. Soler, Roman Perez [corrected to Perez-Soler, Roman].

13.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

14.

Temsirolimus, an inhibitor of mammalian target of rapamycin.

Rini BI.

Clin Cancer Res. 2008 Mar 1;14(5):1286-90. doi: 10.1158/1078-0432.CCR-07-4719. Review. No abstract available.

15.

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM.

Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19. Epub 2008 Feb 25.

16.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

17.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M, Bicknell DC, Bodmer WF, Feller SM.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2358-62. doi: 10.1073/pnas.0712176105. Epub 2008 Feb 7.

18.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P.

J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.

PMID:
18202412
19.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S.

Ann Oncol. 2008 Mar;19(3):508-15. Epub 2007 Nov 12.

PMID:
17998284
20.

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.

Ann Oncol. 2008 Apr;19(4):717-23. Epub 2007 Oct 31.

PMID:
17974556

Supplemental Content

Support Center